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in HepaRG cells involving these antiepileptic drugs (CBZ 
and OXC) and their main metabolites.
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Introduction
Epilepsy is one of the most common serious chronic neu-
rological disorders, affecting 50 million people worldwide 
[1–3]. It is characterized by recurrent unprovoked seizures 
and the main goal of epilepsy treatment is the achievement 
of a complete seizure-freedom without deleterious effects. 
For that, a continuous antiepileptic activity is required, 
which will be achieved only if plasma and brain drug con-
centrations remain continuously at therapeutic levels [4].
Since the beginning of the 1990s several new antiepi-
leptic drugs (AEDs) were approved by the Food and Drug 
Administration and/or by the European Medicines Agency 
[e.g., eslicarbazepine acetate, felbamate, gabapentin, lamo-
trigine, levetiracetam, oxcarbazepine (OXC), pregabalin, 
rufinamide, stiripentol, tiagabine, topiramate, vigabatrin 
and zonisamide]. The majority of these AEDs offers appre-
ciable advantages in terms of their favourable pharma-
cokinetics, improved tolerability and lower potential for 
drug interactions comparatively to the older AEDs [e.g., 
phenobarbital, phenytoin, ethosuximide, carbamazepine 
(CBZ), and valproic acid] [5, 6]. However, despite the large 
therapeutic arsenal of old and new AEDs, approximately 
55–60 % of people with focal epilepsy and up to 20 % of 
patients with primary generalized epilepsy develops drug 
resistance [7]. Hence, many patients are not seizure-free 
even under appropriate pharmacotherapy with the currently 
Abstract A new, sensitive and fast high-performance liq-
uid chromatography–diode-array detection assay is herein 
reported, for the first time, to simultaneously quantify car-
bamazepine (CBZ), oxcarbazepine (OXC), and the active 
metabolites carbamazepine-10,11-epoxide (CBZ-E) and 
licarbazepine (LIC) in HepaRG cell culture medium sam-
ples. Chromatographic separation of analytes (CBZ, CBZ-
E, OXC, LIC) and internal standard (IS) was achieved in 
less than 15 min on a C18-column, at 35 °C, using a mobile 
phase composed of water/methanol/acetonitrile (69:25:6 
v/v/v) pumped at 1 mL min−1. The analytes and IS were 
detected at 215 nm. The method proved to be selective, 
accurate (bias ± 14.6 %), precise (coefficient of varia-
tion ≤13.1 %) and linear (r2 ≥ 0.9901) over the concentra-
tion ranges of 0.1–15 μg mL−1 for CBZ; 0.1–5 μg mL−1 
for CBZ-E and OXC; and 0.1–40 μg mL−1 for LIC. Fur-
thermore, the absolute recovery of the analytes ranged from 
64.5 to 96.9 % and their stability was demonstrated in the 
studied conditions. This validated HPLC assay will be a 
suitable tool to support future in vitro metabolism profiling, 
drug interaction and other pharmacokinetic-based studies 
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available AEDs, including under combination therapy with 
rational polytherapy regimens [5]. Thus, the search for 
novel AEDs with better efficacy and a safer therapeutic 
index is clearly warranted [5–8].
CBZ and OXC are clinically well-established AEDs, 
presenting a substantial overlap in terms of pharmacologi-
cal and therapeutic properties [9]. CBZ and OXC are struc-
turally related drugs that share the dibenzazepine nucleus 
but they differ at the 10-,11-position (Fig. 1). These molec-
ular differences are possibly on the basis of their different 
metabolic profiles. In humans, whereas CBZ undergoes 
oxidative metabolism to carbamazepine-10,11-epoxide 
(CBZ-E), OXC is rapidly reduced to its pharmacologically 
active licarbazepine (LIC) metabolite (Fig. 1) [10–12].
Although clinical benefits are not expected with long-
term CBZ and OXC cotherapy, switching from CBZ to 
OXC is a common practice in patients unsatisfactorily 
treated with CBZ [13–15]. Nevertheless, these drugs are 
commonly used in combination therapy regimens with 
other AEDs in refractory patients [16–18]; actually, when 
monotherapy fails, add-on therapy is an alternative option 
and there are many possible AED combinations based on 
their mechanisms of action and pharmacokinetic interac-
tions. Nowadays, polytherapy regimens with AEDs are 
prevalent and the potential for AEDs to interact results in 
many challenges [18, 19]. These concerns were recently 
reviewed by Landmark and Patsalos [19] and the impor-
tance of the availability of appropriate in vitro models to 
characterize potential interactions involving AEDs was also 
highlighted.
Accordingly, as CBZ and OXC are widely used in 
the clinical practice and taking into account the valu-
able characteristics of the HepaRG cell line, which con-
stitutes a new and promising alternative model to the 
primary human hepatocytes (“gold standard” model) for 
the evaluation of the hepatic drug metabolism in in vitro 
conditions [20], this work was planned to make available 
a useful bioanalytical method to support future in vitro 
pharmacokinetic-based studies in cultured HepaRG cells 
involving CBZ and/or OXC. Among other advantages, 
HepaRG cells possess the metabolic capacity characteris-
tic of primary human hepatocytes and the indefinite pro-
liferation property of hepatoma cell lines, constituting a 
promising in vitro tool to assess the drug metabolite profil-
ing, the hepatic kinetics of drugs and to foresee drug–drug 
interactions [21–23]. In fact, the use of in vitro data for 
the assessment of potential drug–drug interactions is also 
a practice widely accepted by the regulatory authorities in 
the development of new drugs [24].
Hence, to the best of our knowledge, it is herein reported 
for the first time a high-performance liquid chromatogra-
phy method with diode-array detection (HPLC–DAD) to 
quantify CBZ, OXC, and their pharmacologically active 




CBZ, CBZ-E, OXC and primidone (PRM), used as inter-
nal standard (IS), were purchased from Sigma–Aldrich 
(St Louis, MO, USA). LIC was supplied by Tocris Bio-
science (Bristol, UK). Methanol and acetonitrile, both 
of HPLC gradient grade, were purchased from Fisher 
Scientific (Leicestershire, UK) and the ultra-pure water 
(HPLC grade, >18 MΩ cm) was prepared by means of a 
Milli-Q water apparatus from Millipore (Milford, MA, 
USA). Ethyl acetate were purchased from Fisher Scientific 
(Leicestershire, UK). HepaRG cells (lot no. #48588) were 
Fig. 1  Metabolic pathways of carbamazepine (CBZ) and oxcarbaze-
pine (OXC) to their active metabolites carbamazepine-10,11-epoxide 
(CBZ-E) and licarbazepine (LIC), respectively
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obtained from Life Technologies—Invitrogen™ (through 
Alfagene, Portugal). All cell culture reagents including 
Williams’ E medium, foetal bovine serum, hydrocortisone 
hemisuccinate, dimethyl sulfoxide and trypsin–EDTA 
were purchased from Sigma–Aldrich (St Louis, MO, 
USA).
Stock Solutions, Calibration Standards and Quality 
Control Samples
Stock solutions of CBZ (15 mg mL−1), CBZ-E 
(30 mg mL−1), OXC (10 mg mL−1) and LIC 
(10 mg mL−1) were individually prepared by dissolving 
the appropriate amount of each compound in methanol. 
These solutions were then adequately diluted in water–
methanol (50:50, v/v) to obtain the corresponding work-
ing solutions. Afterwards, stock and working solutions 
of drugs and metabolites were properly mixed to afford 
six combined spiking solutions with final concentrations 
1, 2, 6, 20, 80 and 150 μg mL−1 for CBZ; 1, 2, 5, 10, 
30 and 50 μg mL−1 for CBZ-E and OXC; and 1, 2, 10, 
50, 250 and 400 μg mL−1 for LIC. Each one of these 
combined solutions was daily used for spiking aliquots 
of blank supplemented Williams’ E medium to prepare 
six calibration standards in the concentration ranges of 
0.1–15 μg mL−1 for CBZ; 0.1–5 μg mL−1 for CBZ-E 
and OXC; and 0.1–40 μg mL−1 for LIC. Regarding the 
IS, the stock solution was also prepared in methanol 
(2 mg mL−1) and the working solution (500 μg mL−1) 
was obtained through the dilution of an appropriate vol-
ume of the stock solution with water–methanol (50:50, 
v/v). With exception of the IS working solution which 
was daily prepared, all the stock, working and combin-
ing solutions were stored at 4 °C and protected from 
light.
Quality control (QC) samples at three representative 
concentration levels, representing the low (QC1), medium 
(QC2) and high (QC3) ranges of the calibration curves, 
were also independently prepared in supplemented Wil-
liams’ E medium. With that purpose, aliquots of blank sup-
plemented Williams’ E medium were spiked to attain final 
concentrations of 0.3, 7.5 and 13.5 μg mL−1 for CBZ; 0.3, 
2.5 and 4.5 μg mL−1 for CBZ-E and OXC; and 0.3, 20 and 
36 μg mL−1 for LIC. One additional QC sample was also 
prepared at the concentration of the lower limit of quantifi-
cation (QCLLOQ).
Apparatus and Chromatographic Conditions
Chromatographic analysis was carried out using an HPLC 
system (Shimadzu LC-2010A HT Liquid Chromatog-
raphy) coupled with DAD (Shimadzu SPD-M20A). All 
instrumental parts were automatically controlled by Lab-
Solutions software (Shimadzu, Kyoto, Japan). The chro-
matographic separation of CBZ, CBZ-E, OXC, LIC and 
IS was carried out at 35 °C on a reversed-phase LiChro-
CART® Purospher Star column (C18, 55 × 4 mm; 3 µm 
particle size) purchased from Merck KGaA (Darmstadt, 
Germany). An isocratic elution was applied at a flow rate 
of 1.0 mL min−1 with a mobile phase composed of water/
methanol/acetonitrile (69:25:6 v/v/v). The mobile phase 
was filtered through a 0.2 µm filter and degassed ultra-
sonically for 15 min before use. The injection volume was 
20 µL and the wavelength of 215 nm was selected for the 
detection of all compounds.
Sample Preparation and Extraction
Each aliquot (200 µL) of supplemented Williams’ E cul-
ture medium was added with 20 µL of IS working solution, 
300 µL of acetonitrile and then with 1 mL of ethyl acetate. 
Afterwards, the mixture was vortex-mixed for 30 s and 
centrifuged at 13,500 rpm (3 min). The organic layer was 
transferred to a glass tube and the aqueous layer was re-
extracted twice more with ethyl acetate (1 mL each time) 
using the conditions previously described. The combined 
organic phases were evaporated to dryness under a gen-
tle nitrogen stream at 45 °C and then reconstituted with 
100 µL of mobile phase. An aliquot (20 µL) of this final 
sample was injected into the chromatographic system.
Method Validation
The developed method was appropriately validated taking 
into account the international accepted recommendations 
for bioanalytical method validation [25–27]. The validation 
was carried out considering the acceptance criteria pro-
posed for specific validation parameters including selectiv-
ity, linearity, precision, accuracy, lower limit of quantifica-
tion (LLOQ), recovery and stability.
Selectivity
Aiming at testing the chromatographic similarity between 
the supplemented Williams’ E medium collected after the 
culture of HepaRG cells, to reproduce in the best way what 
happens in real metabolic studies, and the simple supple-
mented Williams’ E medium, a set of samples from these 
two related matrices was analysed and compared. To obtain 
aliquots of medium from cultured HepaRG cells the follow-
ing procedures were conducted. HepaRG cells were main-
tained in the Williams’ E medium supplemented with 10 % 
foetal bovine serum, 100 IU mL−1 penicillin, 100 µg mL−1 
streptomycin, 5 µg mL−1 insulin, 2 mM glutamine and 
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5 × 10−5 M hydrocortisone hemisuccinate during 15 days. 
After this period of time the confluence was reached and 
cells were then maintained in the same culture medium but 
supplemented with 2 % dimethyl sulfoxide (differentiation 
medium) for more 15 days to obtain differentiated HepaRG 
cell cultures. It is worthy to mention that HepaRG cell cul-
tures were maintained at 37 °C in humidified air incubator 
with 5 % CO2 and the medium was renewed each 3 days. 
Then, the differentiated HepaRG cells were seeded at a 
high density (4.5 × 105 cells cm−2) in 96-well plates and 
maintained during 48 h. After that, the cells were exposed 
to 200 µL of supplemented Williams’ E medium for 12 h 
and then the total volume of each well was collected and 
300 µL of acetonitrile was immediately added.
Calibration Curve
The linearity of this chromatographic assay was evaluated 
for each analyte within the concentration ranges defined in 
“Stock solutions, calibration standards and quality control 
samples”. For this purpose, calibration curves were pre-
pared using six spiked supplemented Williams’ E medium 
calibration standards and assayed on three different days 
(n = 3). Calibration curves were constructed by plotting the 
analyte–IS peak area ratio as function of the corresponding 
nominal concentrations. The data were fitted to a weighted 
linear regression analysis and the weighting factor that 
yields the best fit of peak–area ratios versus concentration 
is selected [28].
Lower Limit of Quantification
The LLOQ, defined as the lowest concentration of the 
calibration curve which can be measured with adequate 
inter- and intraday precision, and accuracy [26, 27] was 
evaluated by analysing supplemented Williams’ E medium 
samples prepared in replicates. The precision, expressed 
as percentage of the coefficient of variation (CV), cannot 
exceed 20 %; whereas accuracy, expressed by the devia-
tion from nominal concentration value (bias), should be 
within ±20 %.
Precision and accuracy
QC samples analysed on three consecutive days (n = 3) 
at the four concentration levels (QCLLOQ, QC1, QC2 and 
QC3) representative of the calibration range were used to 
investigate the interday precision and accuracy of the assay. 
Similarly, the intraday precision and accuracy were also 
assessed by analysing five sets of QC samples in a single 
day (n = 5). According to the acceptance criteria defined 
by the bioanalytical method validation guidelines the 
intra- and interday precision (expressed as percentage of 
CV) should be lower than or equal to 15 % (or 20 % in the 
LLOQ), and the intra- and interday accuracy (expressed as 
percentage of bias) should be within ±15 % (or ±20 % in 
the LLOQ) [26, 27].
Recovery
The absolute recovery of the analytes from the samples sub-
mitted to the treatment previously described in the “Sample 
Preparation and Extraction” was determined using three 
QC samples (QC1, QC2 and QC3). The recovery was cal-
culated comparing the analytes peak areas from extracted 
QC supplemented Williams’ E medium samples with those 
obtained after direct injection of non-extracted solutions 
at the same nominal concentrations (n = 5). Similarly, the 
recovery of IS was also evaluated at the concentration used 
in sample analysis, calculating the ratio of its peak areas in 
extracted samples and non-extracted solutions.
Stability
The stability of the analytes in supplemented Williams’ 
E medium was investigated for QC1 and QC3 (n = 5). 
The data of the QC samples analysed before (refer-
ence samples) were compared with those obtained after 
being exposed to the experimental conditions for stabil-
ity assessment (stability samples). As stability criterion 
(n = 5), a stability/reference samples ratio of 85–115 % 
was accepted [27, 31]. The short- and long-term stabil-
ity were evaluated, respectively, at room temperature 
for 4 h and −20 °C for 8 days (n = 5), aiming at sim-
ulating sample handling and storage time in the freezer 
before analysis. Moreover, in an attempt to simulate the 
time that samples can remain in the auto-sampler before 
analysis, the post-preparative stability of the analytes in 




The chromatographic separation of CBZ, CBZ-E, OXC and 
LIC in spiked supplemented Williams’ E medium culture 
samples was successfully achieved using the chromato-
graphic conditions previously described. Under these ana-
lytical conditions the last-eluting analyte was CBZ, being 
the run time of approximately 15 min. The order of elution 
of the compounds was the following: PRM (IS), LIC, CBZ-
E, OXC and CBZ. Representative chromatograms of blank 
and spiked supplemented Williams’ E culture medium sam-
ples are shown in Fig. 2.
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Selectivity
The chromatograms obtained by the analysis of blank sam-
ples of supplemented Williams’ E medium collected after 
the culture of HepaRG cells (to reproduce the metabolic 
studies) and those generated by the analysis of blank sam-
ples of the simple supplemented Williams’ E medium were 
broadly comparable. As result, the most convenient blank 
matrix (the simple supplemented Williams’ E medium) was 
chosen for the development and validation of this HPLC–
DAD assay.
Calibration Curves and LLOQs
The calibration curves obtained in supplemented Williams’ 
E culture medium were linear (r2 ≥ 0.9901; Table 1) for all 
the analytes over the concentration range defined in “Stock 
Solutions, Calibration Standards and Quality Control Sam-
ples” and showed a consistent correlation between analyte–
IS peak area ratios and the corresponding nominal concen-
trations. The calibration curves for all the analytes were 
subjected to weighted linear regression analysis using 1/x2 
as the weighting factor, due to the wide calibration range 
and to compensate for heteroscedasticity detected. This fac-
tor was chosen taking into account the plots and the sums 
of absolute percentage of relative error as statistical crite-
ria. The regression equations of the calibration curves and 
the corresponding determination coefficients (r2) achieved 
for each analyte are summarized in Table 1.
The LLOQs were experimentally defined as 
0.1 μg mL−1 for all the analytes (CBZ, CBZ-E, OXC and 
Fig. 2  Typical chromatograms of extracted supplemented Williams’ 
E medium samples generated by the HPLC–DAD assay developed: 
blank supplemented Williams’ E medium (a); supplemented Wil-
liams’ E medium spiked with internal standard (IS) and the analytes 
at concentrations of the lower limit of quantification (b); and supple-
mented Williams’ E medium spiked with IS and the analytes at inter-
mediate concentrations of the calibration ranges (c). CBZ carbamaz-
epine; CBZ-E carbamazepine-10,11-epoxide; PRM primidone; LIC 
licarbazepine; OXC oxcarbazepine
Table 1  Mean calibration parameters obtained for carbamazepine 
(CBZ), carbamazepine-10,11-epoxide (CBZ-E), oxcarbazepine 
(OXC) and licarbazepine (LIC) in supplemented Williams’ E culture 
medium (n = 3)






CBZ 0.1–15 y = 0.0949x + 0.0038 0.9901
CBZ-E 0.1–5 y = 0.1022x + 0.0010 0.9913
OXC 0.1–5 y = 0.0493x + 0.0021 0.9924
LIC 0.1–40 y = 0.0031x + 0.0615 0.9905
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LIC) with acceptable precision (CV ≤17.3 %) and accu-
racy (bias varied from −12.3 to 10.1 %).
Precision and Accuracy
The data for intra- and interday precision and accuracy 
obtained from QC supplemented Williams’ E medium sam-
ples at the four different concentration levels (QCLLOQ, 
QC1, QC2 and QC3) are shown in Table 2. All the data 
fulfilled the acceptance criteria established. Accordingly, 
the overall inter- and intraday CV values did not exceed 
13.1 % (or 17.7 % in the QCLLOQ), and the overall inter- 
and intraday bias values varied between −12.8 and 14.6 % 
(or −12.3–10.1 % in the QCLLOQ), which supports that 
the HPLC–DAD method herein described is precise and 
accurate.
Recovery
The overall absolute recovery of CBZ, CBZ-E, OXC and 
LIC from supplemented Williams’ E culture medium sam-
ples was determined at three concentration levels (QC1, 
QC2 and QC3) by repeated analysis (n = 5). These data 
are shown in Table 3. The mean absolute recoveries ranged 
from 64.5 to 96.9 % and showed CV values lower than 
14.8 % for all analytes (AEDs and metabolites). The recov-
ery of the IS (PRM) was also evaluated, being its absolute 
recovery of 70.2 ± 8.6 % with a CV value of 12.2 %. These 
data undoubtedly support a consistent recovery over the 
evaluated concentration ranges by the sample preparation 
procedure implemented.
Stability
The stability of the CBZ, CBZ-E, OXC and LIC in sup-
plemented Williams’ E culture medium was evaluated 
under the different conditions previously described, which 
simulate the handling and sample storage conditions to be 
likely required during the analytical process. The analytes 
demonstrated to be stable in unprocessed samples at room 
temperature for 4 h and at −20 °C for 8 days and also in 
processed samples at room temperature during 12 h. The 
stability data are shown in Table 4.
Method Application
HepaRG cells were seeded in Williams’ E medium sup-
plemented with 10 % foetal bovine serum, 100 IU mL−1 
penicillin, 100 μg mL−1 streptomycin, 5 μg mL−1 insulin, 
2 mM glutamine and 5 × 10−5 M hydrocortisone hemisuc-
cinate (basal growth medium) and maintained at 37 °C in a 
humidified air incubator with 5 % CO2. The medium was 
renewed every 2–3 days until cells reach confluence, which 
were expanded by gentle trypsinization and maintained in 
Table 2  Inter and intraday precision (% CV) and accuracy (% 
bias) values obtained for carbamazepine (CBZ), carbamazepine-
10,11-epoxide (CBZ-E), oxcarbazepine (OXC) and licarbazepine 
(LIC) in supplemented Williams’ E culture medium samples at the 
concentrations of the lower limit of quantification (*) and at low 
(QC1), medium (QC2) and high (QC3) concentrations representative 
of the calibration ranges
CV coefficient of variation; bias deviation from nominal concentration value
Analyte Nominal concentration (μg mL−1) Interday Intraday
Precision (% CV) Accuracy (% bias) Precision (% CV) Accuracy (% bias)
CBZ 0.1* 17.3 2.5 6.8 −2.8
0.3 8.0 12.7 0.8 13.8
7.5 4.6 −1.4 3.2 −6.7
13.5 3.5 3.1 5.9 −6.9
CBZ-E 0.1* 6.3 −1.6 9.2 10.1
0.3 3.4 5.6 3.7 12.6
2.5 12.2 0.6 1.8 14.6
4.5 4.2 −2.3 6.7 −5.6
OXC 0.1* 10.3 −5.1 10.3 3.3
0.3 4.0 −9.0 4.6 −11.5
2.5 13.1 −0.2 4.9 11.0
4.5 6.1 −2.0 2.5 −11.2
LIC 0.1* 1.3 −12.3 4.7 −5.1
0.3 6.8 6.2 4.3 13.6
20 10.0 −3.5 10.4 −0.2
36 3.2 −10.7 2.8 −12.8
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culture by serial passages and then used when appropriate 
for the specific studies. For the metabolic studies, HepaRG 
cells were maintained in the basal growth medium dur-
ing 15 days. After this period of time the confluence was 
reached and the cells were maintained in the same culture 
medium supplemented with 2 % DMSO (differentiation 
medium) for more 15 days to obtain differentiated Hep-
aRG cell cultures. In both cases, cell cultures were main-
tained at 37 °C in humidified air incubator with 5 % CO2 
and the medium was renewed each 3 days. The differen-
tiated HepaRG cells were then seeded at a high density 
(4.5 × 105 cells cm−2) on 96-well plates. After a period of 
cell adhesion of 24 h, the cells were incubated with 200 µL 
OXC 2.5 μg mL−1 prepared in foetal bovine serum-free 
basal growth medium (0.25 % DMSO). After 2, 4, 6, 12 
and 24 h, the culture medium (200 µL) was collected and 
300 µL of ice-cold acetonitrile was added to each sample to 
stop the metabolic reactions. During the incubation times, 
the cell cultures were maintained at 37 °C in humidified 
air incubator with 5 % CO2. Thereafter, the samples were 
frozen at −20 °C until analysis of OXC and its metabolite 
(LIC). The obtained results are presented in Fig. 3a, show-
ing an increasing formation of LIC over the time while the 
concentration of OXC (parent drug) is gradually reduced. 
In Fig. 3b is shown a chromatogram resulting of the analy-
sis of a real sample obtained at 6 h after incubation of OXC 
(2.5 μg mL−1) with the HepaRG cells.
Discussion
As previously mentioned, besides the availability of more 
than 20 AEDs [1], the truth is that the monotherapy with 
AEDs often fails, requiring polytherapy regimens in an 
attempt to achieve better seizure control and fewer side 
effects [29–32]. Unfortunately, the implementation of 
polytherapy regimens in the clinical practice frequently 
originates complex and unpredictable pharmacokinetic and 
Table 3  Absolute recovery 
of carbamazepine (CBZ), 
carbamazepine-10,11-epoxide 
(CBZ-E), oxcarbazepine (OXC) 
and licarbazepine (LIC) in 
supplemented Williams’ E 
culture medium
a Mean ± standard deviation, n = 5
Analyte Nominal concentration (μg mL−1) Absolute recovery (%)a Precision (% CV)
CBZ 0.3 79.5 ± 4.8 6.1
7.5 68.7 ± 7.1 12.2
13.5 69.4 ± 8.8 14.8
CBZ-E 0.3 87.5 ± 8.0 9.1
2.5 65.1 ± 8.2 12.6
4.5 66.8 ± 6.4 9.6
OXC 0.3 96.9 ± 6.2 6.4
2.5 85.2 ± 2.3 2.7
4.5 82.4 ± 2.5 3.0
LIC 0.3 88.3 ± 8.5 9.6
20 65.1 ± 9.0 13.8
36 64.5 ± 8.8 13.7
Table 4  Stability (values in mean percentage) of carbamazepine 
(CBZ), carbamazepine-10,11-epoxide (CBZ-E), oxcarbazepine 
(OXC) and licarbazepine (LIC) in unprocessed and processed sam-
ples of supplemented Williams’ E culture medium under the expected 
sample handling and storage conditions (n = 5)
Analyte Nominal concentration 
(μg mL−1)
Supplemented Williams’ E culture medium
Unprocessed sample Processed sample
Room temperature (4 h) −20 °C (8 days) Room temperature (12 h)
CBZ 0.3 102.8 106.9 102.5
13.5 98.4 95.2 94.1
CBZ-E 0.3 102.8 108.5 109.2
4.5 99.7 105.7 97.9
OXC 0.3 96.2 105.6 108.1
4.5 98.6 94.5 90.6
LIC 0.3 106.4 110.5 110.8
36 99.7 102.3 92.6
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pharmacodynamic interactions, leading to possible clini-
cal consequences in terms of toxicity or even therapeutic 
inefficacy [30, 33]. In fact, patients with epilepsy are par-
ticularly affected by clinically relevant drug interactions 
[33–35]. This can be explained not only by the long admin-
istration periods of AEDs, often required for a lifetime, 
increasing the probability of coprescription, but also due to 
the narrow therapeutic index of some AEDs (e.g., pheno-
barbital, phenytoin, CBZ, valproic acid); in fact, some of 
these older AEDs (e.g., CBZ, valproic acid) are still widely 
prescribed today and have marked effects on the activ-
ity of cytochrome P450 (CYP) isoenzymes, which also 
metabolize the majority of existing medication, including 
the new generation AEDs [33]. Although other drug inter-
action mechanisms can occur, such as pharmacodynamic-
based interactions, the majority of clinically significant 
AED interactions are result of induction or inhibition of 
drug-metabolizing CYP isoenzymes [33]. The enzyme 
inducers as CBZ, phenytoin and phenobarbital increase 
the activity of a variety of CYP isoenzymes (CYP1A2, 
CYP2C9, CYP2C19 and CYP3A4), as well as glucuronyl 
transferases and epoxide hydrolase, which may enhance 
the drug metabolism and reduce the serum concentra-
tions of other concurrently administered drugs (including 
AEDs) [33, 34, 36]. Actually, although none of the newer 
AEDs shares the broad spectrum enzyme-inducing activ-
ity of those older generation agents, they are also cleared 
fully or partly by inducible CYP isoenzymes, making them 
a target for drug interactions mediated by enzyme induc-
tion [33]. On the other hand, several drugs from other 
therapeutic classes have also been found to increase the 
serum concentration of AEDs, presumably by inhibiting 
their metabolism. For example, several antidepressants like 
fluoxetine, fluvoxamine or trazodone and antimicrobials 
like clarithromycin, erythromycin or fluconazole have been 
reported to interfere in the serum concentrations of CBZ 
[33]. Consequently, whenever possible, these drug interac-
tions should be prevented and early identified [35]. Indeed, 
drug–drug interactions are an essential aspect to be consid-
ered in the process of new drug development, representing 
a major concern for pharmaceutical industry and regulatory 
agencies and at clinical level for healthcare profession-
als and their patients. Therefore, in vitro models are being 
increasingly used during preclinical drug development, 
arising as screening tools to predict drug–drug interactions 
[37–40]. In fact, there is increasing evidence that appropri-
ate in vitro drug interaction studies can accurately reflect 
what happens in in vivo conditions [37, 39]. Indeed, in the 
decision making process during the development of new 
drug candidates, the evaluation of induction and inhibition 
of CYP isoenzymes is one of the major points of concern 
[41, 42]. Although in the past years numerous in vitro and/
or ex vivo models have been developed to investigate drug 
metabolism, the HepaRG cells represent perhaps nowadays 
the most relevant in vitro model as surrogate to the primary 
human hepatocytes, evidencing a great value to foresee 
drug–drug interactions [22, 23].
Several metabolic interactions involving AEDs have 
been identified by means of in vitro models. For instance, 
it is the case of the metabolic interaction between imipra-
mine [43] or felbamate [44] with CBZ. Taking into account 
the experimental advantages of HepaRG cells, the avail-
ability of a rapid, sensitive and reliable analytical method 
is critical to support subsequent metabolic drug interaction 
studies in this kind of biological samples. Up to date, sev-
eral HPLC methods have been developed and validated for 
the determination of these AEDs, and some of their main 
metabolites in several matrices. Most of the methodolo-
gies described in the literature for the simultaneous deter-
mination of CBZ and OXC are HPLC assays using DAD 
or ultraviolet detection [30, 45–50]. Nevertheless, the 
extraction procedures that were applied in the preparation 
Fig. 3  Concentration-time profiles for the metabolism of OXC in its 
active metabolite LIC after 2, 4, 6, 12 and 24 h of incubation of the 
parent drug (OXC) at 2.5 μg mL−1 in differentiated HepaRG cells 
(a); and a representative chromatogram of the analysis of a real sam-
ple obtained after 6 h of incubation of OXC (2.5 μg mL−1) in the dif-
ferentiated HepaRG cells (b). OXC oxcarbazepine, LIC licarbazepine, 
PRM primidone
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of the samples were diversified and included not only the 
liquid–liquid extraction [51], that was also applied in this 
assay, but also solid-phase extraction [30, 45, 47, 49], 
microextraction by packed sorbent [46, 50] and protein 
precipitation [48]. The matrices used in these methodolo-
gies included human plasma [30, 45–48, 50] or urine [50], 
for example. However, none of the HPLC assays described 
permitted the quantification of CBZ or/and OXC, and their 
main metabolites, in culture mediums or even in super-
natants of cell cultures. Actually, the HPLC–DAD assay 
herein described is the first one to quantify CBZ, OXC, and 
their relevant pharmacologically active metabolites (CBZ-E 
and LIC, respectively) in HepaRG cell culture medium.
During the process of drug discovery and development 
the bioanalysis was recognised to be a critical tool, essen-
tial for the pharmacokinetic/pharmacodynamics charac-
terization of a drug. Indeed, there is a continuous need of 
development of analytical methodologies, which permit the 
quantification of not only the drug but also its metabolites 
in several biological samples, supporting various stages of 
the drug discovery and development [52, 53]. However, it 
is accepted that in the latter stages of the process the lev-
els of analytical acceptance criteria become stricter, and it 
is supposed that the results were confirmed by appropri-
ate validation assays, which permit to attest the reliability, 
robustness and accuracy of the methods [52–54]. Neverthe-
less, the degree of development and quality of bioanalyti-
cal assays used in the discovery and development of novel 
chemical entities tends to increase as the lead candidates 
progress to more advanced stages. Actually, the various 
validation criteria defined by the international guidelines 
are not usually applied in the early stages of drug discovery 
and development, being used only minimal standards in the 
higher throughput assays performed in these steps [52–54]. 
All these points could explain the lack of HPLC methodol-
ogies in the literature describing a full bioanalytical method 
validation regarding the in vitro studies. Nonetheless, as we 
intended to develop a robust technique that could provide a 
high level of confidence in the results obtained, the HPLC–
DAD method herein described was extensively validated 
taking into account the international criteria of the US Food 
and Drug Administration (FDA) and by the European Med-
icines Agency (EMA) guidelines.
Conclusion
Until now, to the best of our knowledge, there is no 
reported methodology in the literature to simultaneously 
determine the considered analytes CBZ, CBZ-E, OXC and 
LIC in HepaRG cell culture medium samples. Therefore, 
the present work describes the first HPLC–DAD assay 
developed and fully validated according to the international 
requirements for bioanalytical purposes. Hence, this meth-
odology represents a useful bioanalytical tool to sup-
port future in vitro metabolic, drug interaction and other 
pharmacokinetic-based studies involving these AEDs and 
metabolites in the new and promising in vitro model Hep-
aRG cell line.
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